Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precipio, Inc. (PRPO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly reports, and other key documents filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed healthcare biotechnology company focused on cancer diagnostics, Precipio uses these filings to report on its financial performance, capital structure, and significant corporate events.
Investors can review Precipio’s periodic reports, such as its Quarterly Reports on Form 10-Q, which the company references in its earnings press releases. These filings contain detailed information on revenues from the pathology services and products divisions, gross margin trends, cash flow from operations, and non-GAAP measures such as EBITDA and Adjusted EBITDA, along with reconciliations to GAAP results. They also provide additional context on operating expenses, investments in laboratory and manufacturing capacity, and other factors influencing profitability.
Precipio’s current reports on Form 8-K highlight material events and investor communications. Recent 8-K filings have covered topics such as the termination of an at-the-market Sales Agreement with A.G.P./Alliance Global Partners, shareholder update calls, and the posting of an updated investor presentation. These filings often include press releases or presentation materials as exhibits, giving investors direct access to management’s commentary and strategic updates.
Through its filings, Precipio also discloses information about financing arrangements, warrant exercises, and debt obligations. For example, the company has reported on the termination of its ATM facility, the extent of shares sold under that agreement, and changes in its warrant structure. Press releases referenced in filings further describe the repayment of a Change Healthcare advance and the remaining small loan with the Connecticut Department of Economic and Community Development, providing insight into the company’s debt profile.
On Stock Titan, these SEC documents are supplemented by AI-powered tools that help interpret complex filings. Investors can use AI-generated summaries to understand the main points of lengthy 10-Q or 10-K reports, track Form 8-K events, and quickly identify disclosures related to revenue composition, margins, capital structure changes, and other topics relevant to a specialty cancer diagnostics company like Precipio.
Precipio, Inc. is organizing a Q1-2026 shareholder update call on May 18, 2026 at 5:00 PM ET. Management plans to discuss the company’s current core businesses and overall performance, strategy, and growth initiatives.
For the first time, the quarterly update will feature a dedicated, moderated live Q&A session, allowing investors and other listeners to submit questions during the call or in advance by email. Participants can join by calling 646.307.1865, and a replay will be available on the Investors section of Precipio’s website.
Precipio, Inc. has called its 2026 virtual Annual Meeting of Stockholders for June 15, 2026, at 10 a.m. Eastern Time. Stockholders of record as of April 21, 2026, holding 1,784,830 shares of common stock in total, may attend online, ask questions, and vote using a 16-digit control number.
The agenda includes electing three Class II directors—Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D.—to terms expiring in 2029 and ratifying CBIZ CPAs, P.C. as independent auditor for the year ending December 31, 2026. The board and all key committees are majority independent, with separate chair and CEO roles, and have adopted policies on board diversity, ESG oversight, insider trading, and compensation clawbacks.
The filing details beneficial ownership, with directors and executive officers as a group holding 324,799 shares, or 16.6% of common stock as of the record date. It also outlines director cash retainers and stock option grants, and executive pay that combines salaries, deferred bonus opportunities, and equity awards designed to align leadership incentives with long-term stockholder value.
Valauri Christina Rizopoulos reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Christina Rizopoulos Valauri received a grant of 93 shares of Common Stock on April 15, 2026. According to the footnote, this stock grant was provided as consideration in lieu of cash for her compensation for service on the Board of Directors for Q1-25. Following this equity award, she directly owns 5,520 shares of Precipio common stock.
Cossman Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Jeffrey Cossman received a grant of 365 shares of common stock on April 15, 2026. The shares were issued at $29.49 per share as compensation in lieu of cash for his Board of Directors service for Q1-26, bringing his direct holdings to 16,133 shares.
Cohen David Seth reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director David Seth Cohen received a grant of 445 shares of common stock on April 15, 2026. The shares were issued at $29.49 per share as compensation in lieu of a cash payment for his Board of Directors service for Q1-26. Following this grant, his direct holdings increased to 54,679 common shares.
Precipio, Inc. Chief Operating Officer Ahmed Zaki reported an open-market purchase of common stock. On April 1, 2026, he bought 19 shares at $27.93 per share, increasing his direct holdings to 1,034 shares. The purchase was made under a pre-arranged Rule 10b5-1 trading plan.
Precipio, Inc. files its annual report describing an integrated cancer diagnostics business built around pathology services and proprietary products such as HemeScreen and IV-Cell. The company targets U.S. oncology labs and cites large addressable markets in oncology testing and diagnostic products.
For the year ended December 31, 2025, Precipio recorded an operating loss of $1.2 million, an accumulated deficit of $102.8 million, cash of $2.6 million and working capital of $2.3 million, leading auditors to express substantial doubt about its ability to continue as a going concern. One customer represented 26% of 2025 revenue, and government programs accounted for about 40% of revenue.
The company spent $1.6 million on research and development in 2025, continues to pursue patent protection for its technologies, and operates under complex U.S. and international regulatory regimes, including FDA, CLIA, EU IVDR, UKCA, HIPAA, GDPR and emerging state privacy laws. Management highlights liquidity needs, reimbursement risk, regulatory change, climate-related and macroeconomic pressures as key risk factors.
Precipio, Inc. reported preliminary, unaudited results showing a strong finish to 2025. Full-year 2025 revenues grew about 30% year-over-year. In Q4-2025, the company generated approximately $0.4 million in operating cash flow, reflecting a shift to cash-flow positivity.
Q4-2025 net income was about $0.5 million under GAAP, compared with a net loss of roughly $0.4 million in Q4-2024. Q4-2025 EBITDA was about $0.9 million, and Adjusted EBITDA was about $1.0 million, up from approximately $0.0 million and $0.4 million respectively in Q4-2024.
Management highlights becoming EBITDA- and cash-flow-positive as a key milestone that may allow greater focus on longer-term growth projects. More detailed discussion is expected on a shareholder call in early April, following the planned Form 10-K filing.
Leviticus Partners filed an amended Schedule 13G reporting beneficial ownership of 158,635 shares of Precipio, Inc. common stock, representing 9.1% of the class as of 12/31/2025.
The filer has sole voting and sole dispositive power over all reported shares and states the position is held in the ordinary course of business, not for the purpose of changing or influencing control of Precipio.